Total Synthesis of Nominal Lyngbouilloside Aglycon

The first enantioselective total synthesis of the originally assigned structure of lyngbouilloside aglycon has been achieved using a particularly flexible route featuring an acylketene macrolactonization of a tertiary methyl carbinol as the key step. Comparison of the C13 chemical shifts of our synthetic aglycon with the ones pertaining to natural lyngbouilloside and lyngbyaloside C resulted in a possible stereochemical reassignment of the C11 stereogenic center

Synthesis and Biological Evaluation of Dimeric Furanoid Macroheterocycles: Discovery of New Anticancer Agents

A recently developed dimerization/macrocyclization was employed to synthesize a series of macroheterocycles which were biologically evaluated, leading to the discovery of a number of potent cytotoxic agents (e.g., <b>27</b>: GI₅₀ = 51 nM against leukemia CCRF-CEM cell line; <b>29</b>: GI₅₀ = 99 nM against melanoma MDA-MB-435 cell line). Further biological studies support an apoptosis mechanism of action for these compounds involving deregulation of the tricarboxylic acid cycle activity and suppression of mitochondrial function in cancer cells

Synthesis and Biological Investigation of Δ¹²-Prostaglandin J₃ (Δ¹²-PGJ₃) Analogues and Related Compounds

A series of Δ¹²-prostaglandin J₃ (Δ¹²-PGJ₃) analogues and derivatives were synthesized employing an array of synthetic strategies developed specifically to render them readily available for biological investigations. The synthesized compounds were evaluated for their cytotoxicity against a number of cancer cell lines, revealing nanomolar potencies for a number of them against certain cancer cell lines. Four analogues (<b>2</b>, <b>11</b>, <b>21</b>, and <b>27</b>) demonstrated inhibition of nuclear export through a covalent addition at Cys528 of the export receptor Crm1. One of these compounds (i.e., <b>11</b>) is currently under evaluation as a potential drug candidate for the treatment of certain types of cancer. These studies culminated in useful and path-pointing structure–activity relationships (SARs) that provide guidance for further improvements in the biological/pharmacological profiles of compounds within this class